Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL14496806 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10361572 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL110914 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL20399009 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2028876 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403831 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL329845 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230340451-A1 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | FLAGSHIP PIONEERING, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230181620-A1 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-06-15 | — | — | US | disclosed |
| WO-2020143800-A1 | LIVER-SPECIFIC AMPK AGONIST, PREPARATION METHOD THEREFOR AND USES THEREOF | 凯思凯迪（上海）医药科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| US-10272028-B2 | Cosmetic Compostions | MARY KAY INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9982237-B2 | Compositions and methods for reprograming non-pluripotent cells into pluripotent stem cells | HONG GUAN, LTD. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20180049973-A1 | COSMETIC COMPOSITIONS | ALLUSTRA TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180049973-A1 | COSMETIC COMPOSITIONS | ALLUSTRA TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-9814670-B2 | Cosmetic compositions | MARY KAY INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070207465-A1 | Compositions for the electronic detection of analytes utilizing monolayers | CLINICAL MICRO SENSORS, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1829539-A2 | A method for treating tension-type headache | HEADEXPLORER ApS (DK) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| US-7163929-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181620-A1 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | RNMT, NSUN3, RNGTT | ADORA3 1445/4885ADORA2A 1945/4885ADORA2B 1454/4885 |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | ADORA3 265/4885ADORA2A 264/4885ADORA2B 441/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | ADORA3 3450/4885ADORA2A 4673/4885ADORA2B 3680/4885 |
| US-20180049973-A1 | COSMETIC COMPOSITIONS | TYR, MC1R, GLA | ADORA3 3597/4885ADORA2A 3140/4885ADORA2B 3464/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | ADORA3 1052/4885ADORA2A 1031/4885ADORA2B 1323/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ADORA3 619/4885ADORA2A 573/4885ADORA2B 1024/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | ADORA3 704/4885ADORA2A 306/4885ADORA2B 537/4885 |
| US-10272028-B2 | Cosmetic Compostions | TYR, MC1R, GLA | ADORA3 3988/4885ADORA2A 3788/4885ADORA2B 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.